Skip to content

The clinical value of estrogen receptor ß5 expression in endometrial carcinogenesis

The clinical value of estrogen receptor ß5 expression in endometrial carcinogenesis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035987
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial cancer

Interventions

Sponsors

Shenzhen Second People's Hospital/ the First Affiliated Hospital of Shenzhen University Health Science Center
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Women over 18 years old; 2. Underwent diagnostic curettage or hysteroscopic diagnostic curettage, postoperative pathological diagnosis of normal endometrium (proliferative endometrium), endometrial hyperplasia without atypical hyperplasia, endometrial atypical hyperplasia, endometrial cancer patients; 3. Patients without moderate to severe intrauterine adhesions and previous endometrial exfoliation who can endure diagnostic curettage.

Exclusion criteria

Exclusion criteria: 1. Previous history of malignant tumor, radiotherapy and chemotherapy; 2. Previous tamoxifen use history; 3. Previous use history of all kinds of progesterone, high-efficiency progesterone and other estrogen antagonistic therapy in recent 3 months; 4. Women during pregnancy and within 42 days after delivery.

Design outcomes

Primary

MeasureTime frame
expression level of ERß5;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactZhiying Yu

Shenzhen Second People's Hospital/ the First Affiliated Hospital of Shenzhen University Health Science Center

lizheyzy@163.com+86 13923801588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026